Trials / Completed
CompletedNCT00482352
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Classification Of Acute Lymphoblastic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11,196 (actual)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 1 Year – 30 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
Detailed description
OBJECTIVES: I. Provide a classification guide that will organize the clinical and laboratory data necessary for assigning each patient with newly diagnosed acute lymphoblastic leukemia (ALL) to a specific treatment clinical trial. II. Provide an administrative base to capture classification data for correlative studies accompanying current Children's Oncology Group (COG) ALL treatment clinical trials. III. Provide a central reference guide for all required and research only ALL studies that will be conducted at local and reference laboratories. IV. Provide a mechanism for optional banking of leukemia and germline specimens for current and future research. OUTLINE: Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia). After completion of induction therapy, patients are followed once or twice annually.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2012-04-01
- Completion
- 2023-06-30
- First posted
- 2007-06-05
- Last updated
- 2023-08-03
Locations
200 sites across 6 countries: United States, Australia, Canada, New Zealand, Puerto Rico, Switzerland
Source: ClinicalTrials.gov record NCT00482352. Inclusion in this directory is not an endorsement.